Glimepiride is a third-generation sulfonylurea antidiabetic drug used to treat type 2 diabetes. It has a low solubility and high permeability. Studies have shown glimepiride is effective at reducing fasting plasma glucose and HbA1c levels when taken once daily. Common side effects include dizziness and headaches, but no single side effect occurred in more than 2% of patients. Due to its erratic absorption in diabetic patients, developing it as a floating drug delivery system may help overcome this issue.

1. Glimepiride
Literature Survey
Presentation by
Primary Information Services
www.primaryinfo.com
mailto:primaryinfo@gmail.com

3. Glimepiride is a sulfonylurea
Glimepiride is a sulfonylurea that is pharmacologically distinct from other sulfonylureas
because of differences in receptor-binding properties and potentially selective effects
on ATP-sensitive K+ channels.
• The pharmacokinetic and pharmacodynamic profile of glimepiride makes it suitable
for once-daily dosing.
• The safety and efficacy of glimepiride have been confirmed in studies involving more
than 5000 patients with type 2 diabetes.
• In one study, once-daily doses of 1-8 mg reduced fasting plasma glucose from
baseline by 43-74 mg/dL more than did placebo (p < 0.001), and hemoglobin (Hb)
A1C values decreased by 1.2-1.9% more than with placebo (p < 0.001). Two-thirds of
patients achieved tight control (i.e., HbA1C < or = 7.2%).
• Glimepiride was as effective as second-generation sulfonylureas. The most common
adverse events were dizziness and headache, but no single adverse event occurred
in more than 2% of patients.
https://pubmed.ncbi.nlm.nih.gov/9793597/

7. Glimepiride is an antidiabetic drug which is one of the third generation
sulfonylureas. It belongs to class II, according to the BCS (Biopharmaceutical
Classification System), which is characterized by low solubility and high
permeability
• Glimepiride is second generation new sulfonyl urea oral antidiabetic.
• Glimepiride is poorly soluble in acidic environment. When it is given orally
in healthy people, it absorbs rapidly and completely.
• However, its absorption is erratic in diabetic patients due to impaired
gastric motility or gastric emptying. This erratic absorption of Glimepiride
becomes clinically significant, since the efficacy of short acting
sulfonylurea is dependent upon the absorption rate of the drug.
• Hence, to overcome the above mentioned drawbacks there is a need to
develop Glimepiride as Floating Drug Delivery System (FDDS) and its
evaluation, according to a a research study
Research Study Report

8. Major Manufacturers

10. Imports into INDIA

11. Imports into India – more data